Key result
18F-FDOPA and 18F-MFBG PET/CT show similar metastatic pheochromocytoma detection with unique tracer-specific advantages.
Why the study?
To identify and compare the location of metastatic pheochromocytoma lesions using 18F-FDOPA and 18F-MFBG PET/CT imaging in a clinical trial setting.
Case Report (n=1)
18F-FDOPA and 18F-MFBG PET/CT may show different uptake patterns in metastatic pheochromocytoma lesions, suggesting complementary roles.
Both tracers detect pheochromocytoma metastases with partial discordance; leaves open optimal tracer choice pending larger studies.
A 30-year-old man with pheochromocytoma was hospitalized for hemoptysis without inducement. CT revealed a mass in the left lung, and biopsy pathology under the bronchoscope suggested that it was a pheochromocytoma metastasis. To further identify the location of the metastatic lesions, the patient was enrolled in a clinical trial and underwent 18 F-FDOPA and 18 F-MFBG PET/CT. Images from both examinations showed similar lesions. However, the lesions differed in that the uptake of some lesions was significantly higher with 18 F-FDOPA than with 18 F-MFBG, whereas the para-aortic lesion was active in 18 F-MFBG but not in 18 F-FDOPA.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2023) conducted a case report in Metastatic Pheochromocytoma (n=1). 18F-FDOPA PET/CT vs. 18F-MFBG PET/CT was evaluated on Identification of metastatic lesions. 18F-FDOPA and 18F-MFBG PET/CT showed similar metastatic pheochromocytoma lesions, though 18F-FDOPA had higher uptake in some lesions and 18F-MFBG uniquely identified a para-aortic lesion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: